Life Sciences INDUSTRIES

We represent industry leaders in biotechnology, pharmaceuticals, medical devices and beyond in confronting and resolving challenges in all aspects of the life sciences industry.

Recognized both globally and nationally as a leading life sciences practice, WilmerHale has represented life sciences clients in boardrooms and courtrooms across the United States and Europe for more than four decades. From biotechnology, pharmaceutical and medical device companies at all stages of growth to venture capitalists and investment banks, we understand the business of our life sciences clients and the changing regulatory, competitive and consumer demands that the industry faces. Our work in supporting life sciences clients has led to the group being named a "Practice Group of the Year" by Law360.

Many of our lawyers have advanced degrees in relevant scientific disciplines and more than 100 of our lawyers devote a significant portion of their practice to aspects critical to life sciences clients. Those aspects include corporate finance, licensing and alliances, mergers and acquisitions, patent prosecution and other intellectual property matters, patent and product liability. We also work with clients on securities, litigation and FDA, competition and other regulatory matters.


Sort By
Falber, Stuart M.

Stuart M. Falber

Co-Chair, Life Sciences Group

+1 617 526 6663 (t)

Juran, Belinda M.

Belinda M. Juran

Co-Chair, Technology Transactions and Licensing Practice Group

Co-Chair, Life Sciences Group

+1 617 526 6987 (t)


Brian A. Johnson

Vice Chair, Corporate Practice Group

Co-Chair, Capital Markets

+1 212 937 7206 (t)

Singer, Steven D.

Steven D. Singer

Chair, Transactional Department

+1 212 295 6307 (t)


We have represented life sciences clients in venture financings, public offerings, mergers and acquisitions, licensing agreements and collaborations. We also have protected their innovations through patent prosecution and portfolio development; defended their interests in enterprise-critical patent litigation; and navigated regulatory issues vital to their success.

 Read about some of our recent life sciences transactions.


Our life sciences clients include:

  • Achillion
  • Agios Pharmaceuticals
  • Argos Therapeutics
  • AVEO Pharmaceuticals
  • Bristol-Myers Squibb
  • Cephalon
  • Cerulean Pharma
  • CoNCERT Pharmaceuticals
  • Cynosure
  • Curis
  • Durata Therapeutics
  • Eleven Biotherapeutics
  • Emergent BioSolutions
  • Epizyme
  • Idenix
  • Idera Pharmaceuticals
  • Infinity Pharmaceuticals
  • Karyopharm Therapeutics
  • The Medicines Company
  • Medtronic
  • Merrimack Pharmaceuticals
  • Novartis Pharmaceuticals Corporation
  • Ophthotech Corporation
  • Pacira Pharmaceuticals
  • PerkinElmer
  • PTC Therapeutics
  • Tetraphase Pharmaceuticals
  • Thermo Fisher Scientific
  • uniQure biopharma

Publications & News


March 27, 2015

2015 Corporate Reports

WilmerHale's annual IPO, Venture Capital and M&A Reports offer insights into market conditions and provide comprehensive statistics and analysis that are hard to find elsewhere.

March 12, 2015

WilmerHale Lawyers, Practices Recognized in 2015 Edition of Chambers Global

Thirty-two WilmerHale lawyers are named among "The World's Leading Lawyers for Business" in the 2015 edition of Chambers Global. In addition to these individual accolades, the firm is recognized in 17 practice areas that span six different regions.

March 11, 2015

Thomson Reuters Nominates MacroGenics and Spark Therapeutics for Allicense Breakthrough Alliance Award

WilmerHale is pleased to congratulate clients MacroGenics Inc. and Spark Therapeutics Inc. for having been selected by Thomson Reuters as nominees for the Allicense Breakthrough Alliance Award 2014—an award that honors the creative partnering efforts of business development licensing and M&A professionals.

March 2, 2015

Technical and Scientific Experience

Our ability to provide superior legal representation to technology companies is greatly enhanced by the academic and industry experience of our lawyers in a wide variety of technical and scientific fields.    

February 5, 2015

Thermo Fisher Scientific Strengthens Bioproduction Offering by Acquiring Advanced Scientifics, Inc.

Thermo Fisher Scientific Inc., the world leader in serving science, today announced it has acquired Advanced Scientifics, Inc. (ASI).

December 23, 2014

Jamie Gorelick Inducted into NACD’s 2014 Directorship 100

WilmerHale Partner Jamie Gorelick has been inducted into The National Association of Corporate Directors' (NACD) 2014 Directorship 100, a distinguished honor which annually recognizes the most influential leaders in the boardroom and corporate governance community.

October 21, 2014

Karen Green Featured in Cover Story of New England Super Lawyers

Partner Karen Green is featured on the cover of the 2014 New England Super Lawyers Magazine and is the subject of its story, "The Details and the Big Picture."

October 15, 2014

Restrictions Governing International Trade in Genetic Resources Enter Into Force

On October 12, 2014, the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits from their Utilization entered into international force. The Protocol establishes a new legal framework to govern access to and utilization of genetic resources, including genetic material and any naturally occurring derivative compound.

October 9, 2014

SEC Enforcement Actions Emphasize Importance of Stock Ownership Reporting Obligations for Public Companies and Insiders

On September 10, 2014, the Securities and Exchange Commission announced charges against 28 officers, directors and major stockholders of public companies for violating Section 16(a) and/or Section 13(d) of the Securities Exchange Act of 1934, as amended.

October 8, 2014

Actavis to Acquire Durata Therapeutics, Inc.

On October 6, 2014, WilmerHale client Durata Therapeutics announced that it had entered into a definitive merger agreement with Actavis plc under which a subsidiary of Actavis will commence a tender offer to acquire all of the outstanding shares of Durata common stock.


As a result of our skill and experience in the life sciences field, we have received many accolades, including:

  • Chambers USA: America's Leading Lawyers for Business 2007-2014 named WilmerHale a top law firm for life sciences with attorneys who are "consistently excellent people," "very responsive" and who "continue to stand out." WilmerHale is "a very strong firm" who is "in the top 1%" in the area of life sciences. 
  • Chambers Global 2013, 2014 and 2015 recognized WilmerHale as a leader in life sciences with an "outstanding US practice coupled with international reach."
  • Chambers Europe 2013 recognized WilmerHale as a leader in life sciences in Germany.
  • Law360 has named WilmerHale as a "Life Sciences Practice Group of the Year" for 2013 in its annual competition which recognizes five firms per practice area that have played a key role in the significant matters that made headlines and changed the legal landscape within the past year. This is the fourth consecutive year the firm has been named a "Practice Group of the Year" by Law360.
  • Legal 500 US 2013 ranked WilmerHale among the top law firms for life sciences. In the 2013 edition of the guidebook, a source stated that our firm "brings a great deal of experience to any situation" and says that our firm "has access to additional expertise/resources to help solve any problem."
  • LMG Life Sciences ranked the firm in their 2013 edition in the areas of patent prosecution, corporate, and licensing and collaboration. The firm was also named a "Lifecycle Firm," meaning the firm is regarded as one of the best full-service law firms within the life sciences industry.
  • LMG Life Sciences named WilmerHale the winner of the 2013 "Canadian Impact Deals of the Year" award. The firm was recognized for its representation of Enobia Pharma in the company's acquisition by Alexion Pharmaceuticals, Inc.
  • Managing IP recognized WilmerHale in 2013 as one of the best in the nation and named the firm "National Patent Contentious Firm of the Year" and "Pharmaceutical IP Litigation Firm of the Year."
  • Managing IP named WilmerHale among the top nationally ranked firms in their 2013-14 guide, and received a "Tier 1" ranking in the area of life sciences.
  • PLC Life Sciences Industry Super League 2012 named WilmerHale among the top ten law firms for having "a strong transatlantic life sciences practice."
  • PLC Cross-border Life Sciences Handbook 2011/12, 2009/10, 2008/09, 2007/08 and 2006/07 named WilmerHale a leading law firm in the area of life sciences.
  • The American Lawyer placed WilmerHale on their 2013 "A-List" as one of the nation's leading law firms. This is the tenth year the firm has received this recognition.
  • The American Lawyer recognized WilmerHale as its "IP Litigation Department of the Year" in 2014.
  • The National Law Journal named WilmerHale to the 2012 and 2013 Intellectual Property Hot Lists, which honors firms who demonstrate creative strategies for litigation, patent prosecution, licensing and other transactional work.
  • U.S. News – Best Lawyers® recognized the firm in their 2014 and 2015 "Best Law Firms" lists in the first-tier nationally in biotechnology law, corporate law, intellectual property litigation, patent law, securities, technology law and venture capital law. WilmerHale also received first-tier metropolitan rankings in Boston and New York for biotechnology law and corporate law; and in Boston, San Francisco and Washington DC for intellectual property litigation.